Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects

• Published in: Journal of allergy and clinical immunology Vol. 149; no. 3; pp. 907 - 911.e3
• Main Authors: Pham, Michele N., Murugesan, Kanagavel, Banaei, Niaz, Pinsky, Benjamin A., Tang, Monica, Hoyte, Elisabeth, Lewis, David B., Gernez, Yael
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2022; American Academy of Allergy, Asthma & Immunology
• Subjects: 2019-nCoV Vaccine mRNA-1273 - administration & dosage; 2019-nCoV Vaccine mRNA-1273 - adverse effects; 2019-nCoV Vaccine mRNA-1273 - immunology; ACE2 blocking antibody; Adult; Aged; Antibodies, Viral - biosynthesis; antibody deficiency; B-Lymphocytes - immunology; BNT162 Vaccine - administration & dosage; BNT162 Vaccine - adverse effects; BNT162 Vaccine - immunology; common variable immunodeficiency; Covid-19; COVID-19 - immunology; COVID-19 - prevention & control; Female; Good syndrome; Humans; Immunity, Cellular; Immunity, Humoral; Immunoglobulin G - biosynthesis; mAb; Male; Middle Aged; primary immunodeficiency; Primary Immunodeficiency Diseases - immunology; Retrospective Studies; SARS-CoV-2; SARS-CoV-2 - immunology; SARS-CoV-2 IFN-γ release assay; SARS-CoV-2 spike protein antibody; SARS-CoV-2 vaccination; Spike Glycoprotein, Coronavirus - immunology; T-Lymphocytes - immunology; Young Adult; ACE2 blocking antibody; SARS-CoV-2 vaccination; antibody deficiency; IVIG; mRNA; PID; common variable immunodeficiency; SARS-CoV-2 IFN-γ release assay; mAb; IGRA; COVID-19; EUA; ACE2; CVID; SARS-CoV-2; SARS-CoV-2 spike protein antibody; primary immunodeficiency; CTLA-4; Good syndrome; ELISA
• ISSN: 0091-6749; 1097-6825; 1097-6825
• DOI: 10.1016/j.jaci.2021.11.022

Data on the safety and efficacy of coronavirus disease 2019 (COVID-19) vaccination in people with a range of primary immunodeficiencies (PIDs) are lacking because these patients were excluded from COVID-19 vaccine trials. This information may help in clinical management of this vulnerable patient group. We assessed humoral and T-cell immune responses after 2 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients with PID and functional B-cell defects. A double-center retrospective review was performed of patients with PID who completed COVID-19 mRNA vaccination and who had humoral responses assessed through SARS-CoV-2 spike protein receptor binding domain (RBD) IgG antibody levels with reflex assessment of the antibody to block RBD binding to angiotensin-converting enzyme 2 (ACE2; hereafter referred to as ACE2 receptor blocking activity, as a surrogate test for neutralization) and T-cell response evaluated by an IFN-γ release assay. Immunization reactogenicity was also reviewed. A total of 33 patients with humoral defect were evaluated; 69.6% received BNT162b2 vaccine (Pfizer-BioNTech) and 30.3% received mRNA-1273 (Moderna). The mRNA vaccines were generally well tolerated without severe reactions. The IFN-γ release assay result was positive in 24 (77.4%) of 31 patients. Sixteen of 33 subjects had detectable RBD-specific IgG responses, but only 2 of these 16 subjects had an ACE2 receptor blocking activity level of ≥50%. Vaccination of this cohort of patients with PID with COVID-19 mRNA vaccines was safe, and cellular immunity was stimulated in most subjects. However, antibody responses to the spike protein RBD were less consistent, and, when detected, were not effective at ACE2 blocking. [Display omitted]